2023
Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Ernst M, Navani V, Wells J, Bakouny Z, Donskov F, Basappa N, Wood L, Meza L, Pal S, Szabados B, Powles T, Beuselinck B, McKay R, Lee J, Ernst D, Kapoor A, Yuasa T, Choueiri T, Heng D. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology 2023, 7: 501-508. PMID: 37914579, DOI: 10.1016/j.euo.2023.10.002.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaInternational mRCC Database ConsortiumCytoreductive nephrectomySystemic therapy initiationMetastatic kidney cancerRenal cell carcinomaCombination immunotherapyDeferred CNUpfront CNCN statusPrimary tumorOverall survivalTherapy initiationCell carcinomaInternational Metastatic Renal Cell Carcinoma Database ConsortiumAdvent of novel therapeutic agentsKidney cancerInitiation of systemic therapyDiagnosis of metastatic diseaseTreatment of choiceProportion of patientsCox proportional-hazards regressionCharacterization of patientsIO-based combinationsProportional-hazards regressionA0326 Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
Takemura K, Ernst M, Navani V, Wells J, Bakouny Z, Donskov F, Basappa N, Wood L, Meza L, Pal S, Szabados B, Powles T, Beuselinck B, Mckay R, Lee J, Ernst D, Kapoor A, Yuasa T, Choueiri T, Heng D. A0326 Characterization of patients with metastatic renal cell carcinoma treated with or without cytoreductive nephrectomy in the era of combination immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). European Urology 2023, 83: s473-s474. DOI: 10.1016/s0302-2838(23)00375-5.Peer-Reviewed Original Research
2022
Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium
Takemura K, Navani V, Ernst M, Wells J, Meza L, Pal S, Lee J, Li H, Agarwal N, Alva A, Hansen A, Basappa N, Szabados B, Powles T, Tran B, Hocking C, Beuselinck B, Yuasa T, Choueiri T, Heng D. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Journal Of Urology 2022, 209: 701-709. PMID: 36573926, DOI: 10.1097/ju.0000000000003132.Peer-Reviewed Original ResearchConceptsTKI cohortInternational Metastatic Renal Cell Carcinoma Database ConsortiumComplete responseFirst-line therapyOverall survivalCombination therapyTKI armsTyrosine kinase inhibitor therapyMetastatic renal cell carcinomaNon-clear cell histologyMultiple sites of metastasesTyrosine kinase inhibitor monotherapyBaseline characteristics of patientsResponse rateComplete response rateKinase inhibitor therapyOverall survival benefitSite of metastasisFavorable overall survivalRenal cell carcinomaAdverse clinicopathological featuresCharacterization of patientsReal-world patientsCharacteristics of patientsClinical trial populations1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC)
Takemura K, Navani V, Ernst M, Wells J, Choueiri T, Meza L, Pal S, Lee J, Li H, Agarwal N, Alva A, Hansen A, Basappa N, Szabados B, Powles T, Tran B, Hocking C, Beuselinck B, Yuasa T, Heng D. 1455P Characterization of patients with metastatic renal cell carcinoma achieving complete response to first-line therapies: Results from the international metastatic renal cell carcinoma database consortium (IMDC). Annals Of Oncology 2022, 33: s1209-s1210. DOI: 10.1016/j.annonc.2022.07.1558.Peer-Reviewed Original Research